A similar effect of an OA structural analog was previously found with the semi-synthetic triterpenoid CDDO-Me, which passed phase I/II clinical trials for cancer treatment [51] and which induced an antiproliferative effect in Pgp1, over-expressing KHOSR2 and U-2OSTR cells synergistically with Dox [52]. Here, CD44 is linked to cancer.